Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
11.5 USD | -9.45% | +23.39% | +682.31% |
Apr. 11 | Sector Update: Health Care Stocks Decline Thursday Afternoon | MT |
Apr. 11 | Candel Therapeutics Shares Rise After FDA Orphan Drug Designation for Potential Pancreatic Cancer Drug | MT |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 337M |
---|---|---|---|---|---|
Net income 2024 * | -41M | Net income 2025 * | - | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-12.6
x | P/E ratio 2025 * |
-
| Employees | 42 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 66.98% |
1 day | -9.45% | ||
1 week | +23.39% | ||
Current month | +63.12% | ||
1 month | +110.62% | ||
3 months | +568.60% | ||
6 months | +1,177.78% | ||
Current year | +682.31% |
Managers | Title | Age | Since |
---|---|---|---|
Paul-Peter Tak
CEO | Chief Executive Officer | 64 | 20-08-31 |
Founder | 66 | 01-12-31 | |
Charles Schoch
DFI | Director of Finance/CFO | 39 | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Joseph Papa
BRD | Director/Board Member | 68 | 22-08-07 |
Edward Benz
BRD | Director/Board Member | 78 | 17-08-31 |
Paul Manning
CHM | Chairman | 68 | 18-10-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-17 | 11.5 | -9.45% | 840,597 |
24-05-16 | 12.7 | -9.29% | 1,018,825 |
24-05-15 | 14 | +30.84% | 1,706,623 |
24-05-14 | 10.7 | +4.90% | 584,067 |
24-05-13 | 10.2 | +9.44% | 540,978 |
Delayed Quote Nasdaq, May 17, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+682.31% | 337M | |
-0.09% | 42.12B | |
+49.62% | 42.05B | |
-4.96% | 29.18B | |
+11.18% | 26.02B | |
-21.95% | 18.9B | |
+8.61% | 13.21B | |
+24.73% | 12.17B | |
+28.31% | 12.16B | |
-6.26% | 11.42B |
- Stock Market
- Equities
- CADL Stock